Clinical Trial News and Research

RSS

Senhwa Biosciences to present CX-5461 study results at AACR meeting

Senhwa Biosciences, Inc. announced today that results from research with its first-in-class Pol I inhibitor, CX-5461, will be presented at the 2014 American Association for Cancer Research (AACR) annual meeting held on April 5-9 in San Diego, CA.

27 Mar 2014

pSivida resubmits New Drug Application for ILUVIEN

pSivida Corp., a leader in the development of sustained release, drug delivery products for treating eye diseases, today announced that the New Drug Application for ILUVIEN for the treatment of chronic Diabetic Macular Edema has been resubmitted to the U.S. Food and Drug Administration (FDA).

27 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Echo Therapeutics reports net loss of $3.9M in fourth quarter 2013

Echo Therapeutics, Inc., a medical device company developing its Symphony® CGM System as a non-invasive, wireless continuous glucose monitoring system, today announced financial results for the year ended December 31, 2013.

27 Mar 2014

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Updated Phase 1/2a results with GEN-003, a vaccine candidate under development by Genocea Biosciences, Inc. (Nasdaq: GNCA) for the treatment of herpes simplex virus type 2 (HSV-2) infection, showed the experimental vaccine to generate highly significant reductions in both the number of clinical lesion days and rate of viral shedding at six months after the final vaccine dose.

27 Mar 2014

Study seeks to adapt multi-family group treatment approach for people with spinal cord injury

Every year, more than 12,000 Americans-mostly young men-suffer spinal cord injuries in car crashes, falls, sports and acts of violence. Those dealing with this life-changing condition may soon have a better way to cope, thanks to a new collaborative research project by Washington State University Spokane and St. Luke's Rehabilitation Institute.

27 Mar 2014

EORTC study does not support combination chemotherapy for soft tissue sarcoma

An EORTC study published in The Lancet Oncology does not support administration of intensified doxorubicin and ifosfamide for palliation of advanced soft tissue sarcoma, unless the objective is to shrink the tumor.

27 Mar 2014

Egalet provides business update, reports full year 2013 financial results

Egalet Corporation ("Egalet") today reported business highlights and financial results for the year ended December 31, 2013. This marks the first time that Egalet is reporting its operating results as a public company.

26 Mar 2014

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Mast Therapeutics, Inc. today reported financial results for the fourth quarter and year ended December 31, 2013.

26 Mar 2014

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

Insmed Incorporated today reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections.

26 Mar 2014

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

Concordia Healthcare Corp. announced today that its subsidiary Pinnacle Biologics, Inc., a biopharmaceutical research and development company specializing in rare diseases, was granted U.S. Food and Drug Administration premarket supplemental approval (PMA) for its Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber.

26 Mar 2014

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

AM-Pharma B.V., a biopharmaceutical company focused on the development of recAP (recombinant human Alkaline Phosphatase) for inflammatory indications, announces the results of its Phase I trial with both single and multiple ascending doses, which demonstrate that recAP is safe and well tolerated at all doses.

26 Mar 2014

Cogstate's cognition test to play key role in A4 trial for Alzheimer’s disease

Cognition testing technology developed by Cogstate will be used to track the neurological health of elderly people involved in the multinational Phase III clinical trial of a promising new Alzheimer’s disease (AD) drug.

26 Mar 2014

Study finds effectiveness of brief behavioral and mental health programs in pediatric practices

Brief behavioral and mental health programs for children can be effectively provided within pediatric practices as an alternative to being referred to a community specialist, University of Pittsburgh Schools of the Health Sciences researchers found in a National Institutes of Health-funded randomized trial.

26 Mar 2014

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

ZS Pharma, a specialty pharmaceutical company developing novel treatments for kidney, cardiovascular and liver disorders, today announced that it has begun enrolling patients in ZS004, its second Phase 3 clinical trial of ZS-9, a novel investigational treatment for hyperkalemia.

25 Mar 2014

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

BIND Therapeutics, Inc., a clinical-stage nanomedicine platform company developing targeted and programmable therapeutics called AccurinsTM, today reported financial results for the fourth quarter and year-ended December 31, 2013.

25 Mar 2014

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

PatientPoint announced today that they have entered into a distribution agreement with HealthTronics IT Solutions to deliver population health management solutions within urology to drive improved adherence and compliance.

25 Mar 2014

Endogenous tissue growth: an interview with Laurent Grandidier, CEO, Xeltis

ETG or Endogenous Tissue Growth is a new therapeutic category in which surgeons use implants designed to allow the body to repair itself by spontaneously growing natural, healthy tissue from the inside without the use of stem cells or animal-derived products.

25 Mar 2014

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

Exelixis, Inc. today announced that the European Commission has approved COMETRIQ (cabozantinib) for the treatment of adult patients with progressive, unresectable locally advanced or metastatic medullary thyroid carcinoma (MTC).

25 Mar 2014

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

Scientists from Weill Cornell Medical College and Houston Methodist have found that a gene previously unassociated with breast cancer plays a pivotal role in the growth and progression of the triple negative form of the disease, a particularly deadly strain that often has few treatment options. Their research, published in this week's Nature, suggests that targeting the gene may be a new approach to treating the disease.

25 Mar 2014

Clinical Trial News and Research

Senhwa Biosciences to present CX-5461 study results at AACR meeting

pSivida resubmits New Drug Application for ILUVIEN

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Echo Therapeutics reports net loss of $3.9M in fourth quarter 2013

Experimental vaccine for HSV-2 infection reduces rate of viral shedding at 6 months

Study seeks to adapt multi-family group treatment approach for people with spinal cord injury

EORTC study does not support combination chemotherapy for soft tissue sarcoma

Egalet provides business update, reports full year 2013 financial results

Mast Therapeutics reports net loss of $5.7 million for fourth quarter 2013

Insmed reports results from ARIKAYCE phase 2 trial for treatment resistant NTM lung infections

FDA grants PMA for Pinnacle's Optiguide DCYL700 Fiber Optic Diffuser Series flexible fiber

AM-Pharma reports positive results from recAP Phase I trial for Acute Kidney Injury

Cogstate's cognition test to play key role in A4 trial for Alzheimer’s disease

Study finds effectiveness of brief behavioral and mental health programs in pediatric practices

ZS Pharma starts patient enrollment in ZS-9 Phase 3 trial for treatment of hyperkalemia

BIND Therapeutics reports revenue of $2.1 million for fourth quarter 2013

PatientPoint signs distribution agreement with HealthTronics IT Solutions for urology technology

Endogenous tissue growth: an interview with Laurent Grandidier, CEO, Xeltis

European Commission approves Exelixis' COMETRIQ for treatment of progressive, metastatic MTC

XBP1 gene plays pivotal role in the growth and progression of triple negative breast cancer

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Editorial Focus eBook - Proteomics (2nd Edition)

Industry Focus eBook - Life Science Microscopy (2nd Edition)

Biologics stability screening toolkit: Three practical workflows for accelerating formulation development

Event guide: 2nd World RNA-Based Therapeutics & Vaccines Summit Korea

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery